LOGIN  |  REGISTER
Amneal Pharmaceuticals
C4 Therapeutics

Brookdale Senior Living Reports September 2024 Occupancy

October 08, 2024 | Last Trade: US$7.62 0.02 -0.26

NASHVILLE, Tenn., Oct. 8, 2024 /PRNewswire/ -- Brookdale Senior Living Inc. (NYSE: BKD) reported today its consolidated occupancy for September 2024.

September 2024 Observations:

  • September weighted average occupancy increased 30 basis points sequentially to 79.2%, while month end occupancy grew to 80.5%.
  • September represents the Company's thirty-fifth consecutive month of year-over-year weighted average occupancy growth.
  • Third quarter weighted average occupancy increased 130 basis points when compared to the third quarter of 2023, and 80 basis points when compared to the second quarter of 2024.
  • Third quarter move-ins and move-outs were favorable sequentially to the second quarter.

About Brookdale Senior Living

Brookdale Senior Living Inc. is the nation's premier operator of senior living communities. The Company is committed to its mission of enriching the lives of the people it serves with compassion, respect, excellence, and integrity. The Company, through its affiliates, operates independent living, assisted living, memory care, and continuing care retirement communities. Through its comprehensive network, Brookdale helps to provide seniors with care, connection, and services in an environment that feels like home. The Company's expertise in healthcare, hospitality, and real estate provides residents with opportunities to improve wellness, pursue passions, make new friends, and stay connected with loved ones. Brookdale, through its affiliates, operates and manages 648 communities in 41 states as of September 30, 2024, with the ability to serve approximately 58,000 residents. Brookdale's stock trades on the New York Stock Exchange under the ticker symbol BKD. For more information, visit brookdale.com or connect with Brookdale on Facebook or YouTube.

Assertio

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page